Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Lanifibranor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,643Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inventiva Publishes Lanifibranor Trial Results In T2D, MASLD
    Inventiva Publishes Lanifibranor Trial Results In T2D, MASLD

    29 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/29/3017552/0/en/Inventiva-announces-the-publication-of-the-results-from-the-investigator-initiated-proof-of-concept-clinical-trial-evaluating-lanifibranor-in-patients-with-T2D-and-MASLD-in-the-Jou.html

    GLOBENEWSWIRE
    29 Jan 2025
    Share Share
    Legend Study On Lanifibranor In MASH At EASL SLD Summit 2025
    Legend Study On Lanifibranor In MASH At EASL SLD Summit 2025

    22 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/22/3013844/0/en/Results-of-LEGEND-evaluating-lanifibranor-in-combination-with-empagliflozin-in-MASH-selected-for-oral-presentation-at-the-upcoming-EASL-SLD-Summit-2025.html

    GLOBENEWSWIRE
    22 Jan 2025
    Share Share
    Inventiva to Present Ph 2 Lanifibranor & Empagliflozin Data at AASLD
    Inventiva to Present Ph 2 Lanifibranor & Empagliflozin Data at AASLD

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2982240/0/en/Inventiva-will-present-data-from-the-final-analysis-of-the-Phase-2-study-evaluating-the-combination-of-lanifibranor-with-empagliflozin-in-patients-with-MASH-and-T2D-at-the-AASLD-Th.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    Inventiva Receives Positive NATiV3 Phase 3 DMC Recommendation
    Inventiva Receives Positive NATiV3 Phase 3 DMC Recommendation

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2972018/0/en/Inventiva-announces-the-positive-recommendation-of-the-fifth-DMC-of-the-NATiV3-Phase-3-clinical-trial-with-lanifibranor-in-patients-with-MASH.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Inventiva Gets New Patent In Japan For Lanifibranor
    Inventiva Gets New Patent In Japan For Lanifibranor

    25 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/25/2919173/0/en/Inventiva-secures-a-new-patent-in-Japan-expanding-the-IP-protection-of-its-lead-product-candidate-lanifibranor.html

    GLOBENEWSWIRE
    25 Jul 2024
    Share Share
    Inventiva announces a €20.1 million issuance of royalty certificates
    Inventiva announces a €20.1 million issuance of royalty certificates

    18 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/18/2915047/0/en/Inventiva-announces-a-20-1-million-issuance-of-royalty-certificates.html

    GLOBENEWSWIRE
    18 Jul 2024
    Share Share